$CDTX
Cidara Therapeutics, Inc.

2021 Q4 Form 10-K Financial Statement

#000161061822000007 Filed on March 07, 2022

View on sec.gov

Income Statement

Concept 2021 Q4 2021 2020 Q4
Revenue $7.225M $49.57M $3.730M
YoY Change 93.7% 310.7% 104.95%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.982M $18.74M $4.150M
YoY Change 20.05% 17.86% -5.9%
% of Gross Profit
Research & Development $19.01M $73.09M $21.13M
YoY Change -10.02% 7.45% 83.9%
% of Gross Profit
Depreciation & Amortization $37.00K $189.0K $70.00K
YoY Change -47.14% -34.83% -12.5%
% of Gross Profit
Operating Expenses $24.00M $91.83M $25.28M
YoY Change -5.08% 9.43% 59.04%
Operating Profit -$42.26M
YoY Change -41.19%
Interest Expense -$33.00K -$212.0K -$90.00K
YoY Change -63.33% -19.08% -250.0%
% of Operating Profit
Other Income/Expense, Net -$212.0K
YoY Change -19.08%
Pretax Income -$16.80M -$42.47M -$21.63M
YoY Change -22.32% -41.11% 54.28%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$16.80M -$42.47M -$21.63M
YoY Change -22.32% -41.11% 54.28%
Net Earnings / Revenue -232.57% -85.67% -579.89%
Basic Earnings Per Share -$0.81
Diluted Earnings Per Share -$260.1K -$0.81 -$489.7K
COMMON SHARES
Basic Shares Outstanding 66.69M shares 43.94M shares
Diluted Shares Outstanding 52.45M shares

Balance Sheet

Concept 2021 Q4 2021 2020 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $59.68M $59.68M $35.90M
YoY Change 66.24% 66.24% -28.63%
Cash & Equivalents $59.68M $59.68M $35.91M
Short-Term Investments
Other Short-Term Assets $6.662M $6.662M $10.10M
YoY Change -34.04% -34.04% 1.0%
Inventory
Prepaid Expenses
Receivables $5.356M $5.356M $11.18M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $71.70M $71.70M $57.19M
YoY Change 25.37% 25.35% -13.1%
LONG-TERM ASSETS
Property, Plant & Equipment $256.0K $2.543M $342.0K
YoY Change -25.15% 111.92% -20.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.084M $1.084M $2.023M
YoY Change -46.42% -45.8% 83.74%
Total Long-Term Assets $3.627M $3.627M $3.233M
YoY Change 12.19% 13.34% 2.25%
TOTAL ASSETS
Total Short-Term Assets $71.70M $71.70M $57.19M
Total Long-Term Assets $3.627M $3.627M $3.233M
Total Assets $75.33M $75.33M $60.42M
YoY Change 24.66% 24.71% -12.4%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.301M $1.301M $4.568M
YoY Change -71.52% -71.72% 142.08%
Accrued Expenses $10.20M $16.20M $7.959M
YoY Change 28.13% 23.7% 95.65%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.591M $2.591M $7.000M
YoY Change -62.99% -62.99% -30.0%
Total Short-Term Liabilities $34.02M $34.02M $38.56M
YoY Change -11.79% -11.87% 27.7%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $19.74M $19.74M $11.10M
YoY Change 77.79% 77.79%
Total Long-Term Liabilities $19.74M $19.74M $11.10M
YoY Change 77.79% 77.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.02M $34.02M $38.56M
Total Long-Term Liabilities $19.74M $19.74M $11.10M
Total Liabilities $53.75M $53.75M $49.71M
YoY Change 8.13% 8.15% 59.63%
SHAREHOLDERS EQUITY
Retained Earnings -$377.2M -$334.7M
YoY Change 12.69% 28.82%
Common Stock $398.7M $345.4M
YoY Change 15.44% 16.04%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $21.57M $21.57M $10.72M
YoY Change
Total Liabilities & Shareholders Equity $75.33M $75.33M $60.42M
YoY Change 24.66% 24.71% -12.4%

Cashflow Statement

Concept 2021 Q4 2021 2020 Q4
OPERATING ACTIVITIES
Net Income -$16.80M -$42.47M -$21.63M
YoY Change -22.32% -41.11% 54.28%
Depreciation, Depletion And Amortization $37.00K $189.0K $70.00K
YoY Change -47.14% -34.83% -12.5%
Cash From Operating Activities -$14.91M -$25.23M -$11.13M
YoY Change 33.94% -53.63% -26.73%
INVESTING ACTIVITIES
Capital Expenditures $0.00 $41.00K $0.00
YoY Change -77.96%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities $0.00 -$41.00K $0.00
YoY Change -77.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $12.48M
YoY Change 13.06%
Debt Paid & Issued, Net $4.444M
YoY Change 49.98%
Cash From Financing Activities 36.88M $44.60M 410.0K
YoY Change 8893.9% 19.63% -75.0%
NET CHANGE
Cash From Operating Activities -14.91M -$25.23M -11.13M
Cash From Investing Activities 0.000 -$41.00K 0.000
Cash From Financing Activities 36.88M $44.60M 410.0K
Net Change In Cash 21.97M $19.32M -10.72M
YoY Change -304.93% -211.58% -20.89%
FREE CASH FLOW
Cash From Operating Activities -$14.91M -$25.23M -$11.13M
Capital Expenditures $0.00 $41.00K $0.00
Free Cash Flow -$14.91M -$25.27M -$11.13M
YoY Change 33.94% -53.71% -26.73%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001610618
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-36912
CY2021 dei Entity Registrant Name
EntityRegistrantName
CIDARA THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1537286
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
6310 Nancy Ridge Drive,
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 101
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego,
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
CY2021 dei City Area Code
CityAreaCode
(858)
CY2021 dei Local Phone Number
LocalPhoneNumber
752-6170
CY2021 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 Par Value
CY2021 dei Trading Symbol
TradingSymbol
"CDTX"
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q2 dei Entity Public Float
EntityPublicFloat
98000000 USD
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
68154642 shares
CY2021 dei Auditor Name
AuditorName
Ernst & Young LLP
CY2021 dei Auditor Location
AuditorLocation
San Diego, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
59680000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35912000 USD
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2593000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7037000 USD
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5356000 USD
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
11175000 USD
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4069000 USD
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3067000 USD
CY2021Q4 us-gaap Assets Current
AssetsCurrent
71698000 USD
CY2020Q4 us-gaap Assets Current
AssetsCurrent
57191000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
342000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2287000 USD
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
868000 USD
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1084000 USD
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2023000 USD
CY2021Q4 us-gaap Assets
Assets
75325000 USD
CY2020Q4 us-gaap Assets
Assets
60424000 USD
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1301000 USD
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4568000 USD
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
10198000 USD
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7959000 USD
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4859000 USD
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4210000 USD
CY2021Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Current Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerCurrentLiability
13920000 USD
CY2020Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Current Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerCurrentLiability
13865000 USD
CY2021Q4 us-gaap Loans Payable Current
LoansPayableCurrent
2591000 USD
CY2020Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7023000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1148000 USD
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
939000 USD
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
34017000 USD
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38564000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1322000 USD
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0 USD
CY2021Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Noncurrent Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
18413000 USD
CY2020Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Noncurrent Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
11145000 USD
CY2021Q4 us-gaap Liabilities
Liabilities
53752000 USD
CY2020Q4 us-gaap Liabilities
Liabilities
49709000 USD
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
USD
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
67863674 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
67863674 shares
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
44876408 shares
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
44876408 shares
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
7000 USD
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
398733000 USD
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345411000 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377167000 USD
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-334700000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21573000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10715000 USD
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
75325000 USD
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
60424000 USD
CY2021 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
49572000 USD
CY2020 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
12067000 USD
CY2019 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
20915000 USD
CY2021 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
49572000 USD
CY2020 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
12067000 USD
CY2019 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
20915000 USD
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
73087000 USD
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
68017000 USD
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
46401000 USD
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18740000 USD
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15899000 USD
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16238000 USD
CY2021 us-gaap Operating Expenses
OperatingExpenses
91827000 USD
CY2020 us-gaap Operating Expenses
OperatingExpenses
83916000 USD
CY2019 us-gaap Operating Expenses
OperatingExpenses
62639000 USD
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-42255000 USD
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-71849000 USD
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-41724000 USD
CY2021 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2020 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
0 USD
CY2019 us-gaap Gain Loss On Derivative Instruments Net Pretax
GainLossOnDerivativeInstrumentsNetPretax
411000 USD
CY2021 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-212000 USD
CY2020 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-262000 USD
CY2019 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
221000 USD
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-212000 USD
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-262000 USD
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
632000 USD
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-42467000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42467000 USD
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72111000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-72111000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41092000 USD
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-41092000 USD
CY2021 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2020 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
2762000 USD
CY2019 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
0 USD
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-42467000 USD
CY2020 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-74873000 USD
CY2019 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41092000 USD
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.81
CY2021 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.81
CY2020 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.80
CY2020 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.80
CY2019 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.37
CY2019 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.37
CY2021 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
52453452 shares
CY2021 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
52453452 shares
CY2020 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41557350 shares
CY2020 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
41557350 shares
CY2019 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
29934809 shares
CY2019 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
29934809 shares
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
59139000 USD
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5289000 USD
CY2019 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
7000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
411000 USD
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
5073000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41092000 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
37835000 USD
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000 USD
CY2020 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
74804 shares
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
493000 USD
CY2020 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4090000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-72111000 USD
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
10715000 USD
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12316000 USD
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6000 USD
CY2021 us-gaap Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
106725 shares
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
437000 USD
CY2021 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
4014000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42467000 USD
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
21573000 USD
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-42467000 USD
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-72111000 USD
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-41092000 USD
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
189000 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
286000 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
328000 USD
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
4014000 USD
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4090000 USD
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
5073000 USD
CY2021 us-gaap Paid In Kind Interest
PaidInKindInterest
12000 USD
CY2020 us-gaap Paid In Kind Interest
PaidInKindInterest
16000 USD
CY2019 us-gaap Paid In Kind Interest
PaidInKindInterest
28000 USD
CY2021 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
3000 USD
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
5000 USD
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
8000 USD
CY2021 cdtx Operating Lease Right Of Use Amortization
OperatingLeaseRightOfUseAmortization
-1419000 USD
CY2020 cdtx Operating Lease Right Of Use Amortization
OperatingLeaseRightOfUseAmortization
764000 USD
CY2019 cdtx Operating Lease Right Of Use Amortization
OperatingLeaseRightOfUseAmortization
-1713000 USD
CY2021 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
CY2020 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
0 USD
CY2019 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
411000 USD
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-5819000 USD
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
11165000 USD
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
10000 USD
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
229000 USD
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1682000 USD
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2936000 USD
CY2021 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1093000 USD
CY2020 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
6591000 USD
CY2019 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-784000 USD
CY2021 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1085000 USD
CY2020 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1045000 USD
CY2019 us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1244000 USD
CY2021 cdtx Increase Decrease In Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
7323000 USD
CY2020 cdtx Increase Decrease In Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
15207000 USD
CY2019 cdtx Increase Decrease In Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
IncreaseDecreaseInRevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
9803000 USD
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1531000 USD
CY2020 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-821000 USD
CY2019 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
1760000 USD
CY2021 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-170000 USD
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25232000 USD
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54411000 USD
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28532000 USD
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
41000 USD
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
186000 USD
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
35000 USD
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-41000 USD
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-186000 USD
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35000 USD
CY2021 cdtx Proceeds From Issuance Of Common Stock In Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering
36552000 USD
CY2020 cdtx Proceeds From Issuance Of Common Stock In Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering
0 USD
CY2019 cdtx Proceeds From Issuance Of Common Stock In Underwritten Public Offering
ProceedsFromIssuanceOfCommonStockInUnderwrittenPublicOffering
0 USD
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
12483000 USD
CY2020 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
11041000 USD
CY2019 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5289000 USD
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6000 USD
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
14000 USD
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
7000 USD
CY2021 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2020 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
CY2019 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
31000 USD
CY2021 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
4444000 USD
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2963000 USD
CY2019 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0 USD
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
44597000 USD
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37278000 USD
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14273000 USD
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19324000 USD
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-17319000 USD
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14294000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42949000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60268000 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
74562000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62273000 USD
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
42949000 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
60268000 USD
CY2021 us-gaap Interest Paid Net
InterestPaidNet
228000 USD
CY2016Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.54
CY2020 us-gaap Interest Paid Net
InterestPaidNet
445000 USD
CY2019 us-gaap Interest Paid Net
InterestPaidNet
616000 USD
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2341000 USD
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
78000 USD
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
12000 USD
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
10000 USD
CY2021 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
437000 USD
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
493000 USD
CY2019 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
411000 USD
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
167000 USD
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
0 USD
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-377200000 USD
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
62300000 USD
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. The Company evaluates its estimates and assumptions on an ongoing basis. The most significant estimates in the Company’s consolidated financial statements relate to estimating the fair value of the Company’s stock options, estimated collaboration expenses and incurred expenses related to the Mundipharma Collaboration Agreement and Janssen Collaboration Agreement (as defined below), certain accruals, including those related to nonclinical and clinical activities, and the Standalone Selling Price of performance obligations associated with license agreements. Although the estimates are based on the Company’s knowledge of current events, comparable companies, and actions it may undertake in the future, actual results may ultimately materially differ from these estimates and assumptions.</span></div>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains deposits in government insured financial institutions in excess of government insured limits. The Company invests its cash balances in financial institutions that it believes have high credit quality, has not experienced any losses on such accounts and does not believe it is exposed to significant credit risk.</span></div>
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40172226 shares
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
29747141 shares
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23530201 shares
CY2016Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
17331 shares
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
59680000 USD
CY2021Q4 cdtx Restricted Cash And Cash Equivalents Fair Value Disclosure
RestrictedCashAndCashEquivalentsFairValueDisclosure
2593000 USD
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
62273000 USD
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
35912000 USD
CY2020Q4 cdtx Restricted Cash And Cash Equivalents Fair Value Disclosure
RestrictedCashAndCashEquivalentsFairValueDisclosure
7037000 USD
CY2020Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
42949000 USD
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3480000 USD
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3394000 USD
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3224000 USD
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3052000 USD
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
256000 USD
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
342000 USD
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000 USD
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000 USD
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000 USD
CY2021 cdtx Common Stock Dividends In Arrears Or Default
CommonStockDividendsInArrearsOrDefault
0 USD
CY2016Q4 cdtx Classof Warrantor Right Percentageof Principalof Debt Usedto Calculate Numberof Shares Issuedby Warrant
ClassofWarrantorRightPercentageofPrincipalofDebtUsedtoCalculateNumberofSharesIssuedbyWarrant
0.020
CY2016Q4 cdtx Classof Warrantor Right Periodof Average Closing Price Usedto Calculate Numberof Shares Issuedby Warrant
ClassofWarrantorRightPeriodofAverageClosingPriceUsedtoCalculateNumberofSharesIssuedbyWarrant
P30D
CY2016Q4 cdtx Classof Warrantor Right Term
ClassofWarrantorRightTerm
P10Y
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
2600000 USD
CY2020Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
7000000 USD
CY2021 us-gaap Interest Expense Debt
InterestExpenseDebt
12000 USD
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
21000 USD
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
36000 USD
CY2021Q4 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
15.50
CY2021Q4 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
36600000 USD
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021 cdtx Number Of Votes Entitlement For Each Share Held
NumberOfVotesEntitlementForEachShareHeld
1 vote
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
43289438 shares
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
33082258 shares
CY2019Q4 cdtx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Per Share Exercise Price Of Eligible Shares Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationPerShareExercisePriceOfEligibleSharesMinimum
2.28
CY2019Q4 cdtx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of Eligible Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEligibleShares
1656379 shares
CY2019Q4 cdtx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Percentage Of Eligible Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationPercentageOfEligibleShares
0.604
CY2019Q4 cdtx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Number Of New Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfNewShares
1529814 shares
CY2019Q4 cdtx Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Per Share Exercise Price Of New Shares
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationPerShareExercisePriceOfNewShares
2.45
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost
700000 USD
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
6358798 shares
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.59
CY2020 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y14D
CY2020Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
55000 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
2981200 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.38
CY2021 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2930 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.98
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1040977 shares
CY2021 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
8296091 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y3M21D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8296091 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
3.21
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y3M21D
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 USD
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
5377439 shares
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.71
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y10M13D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 USD
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.42
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.48
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.78
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3700000 USD
CY2021 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y3M18D
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4014000 USD
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4090000 USD
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5073000 USD
CY2021Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Current Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerCurrentLiability
13920000 USD
CY2021Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Noncurrent Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
18413000 USD
CY2021Q4 cdtx Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer Liability
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerLiability
32333000 USD
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2021 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8918000 USD
CY2020 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-15142000 USD
CY2019 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-8629000 USD
CY2021 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1426000 USD
CY2020 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-469000 USD
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1899000 USD
CY2021 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
339000 USD
CY2020 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
486000 USD
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense
IncomeTaxReconciliationNondeductibleExpense
561000 USD
CY2021 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2487000 USD
CY2020 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
2956000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4141000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-30000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
344000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
-664000 USD
CY2021 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
11789000 USD
CY2020 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
15912000 USD
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
13692000 USD
CY2021 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
622000 USD
CY2020 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
739000 USD
CY2019 us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
1035000 USD
CY2021 cdtx Effective Income Tax Rate Reconciliation162 M Deferred Tax Asset Limitation Amount
EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount
76000 USD
CY2020 cdtx Effective Income Tax Rate Reconciliation162 M Deferred Tax Asset Limitation Amount
EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount
857000 USD
CY2019 cdtx Effective Income Tax Rate Reconciliation162 M Deferred Tax Asset Limitation Amount
EffectiveIncomeTaxRateReconciliation162MDeferredTaxAssetLimitationAmount
0 USD
CY2021 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
35000 USD
CY2020 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
229000 USD
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
45000 USD
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
68146000 USD
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
62238000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
21195000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
19330000 USD
CY2021Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
197000 USD
CY2020Q4 us-gaap Deferred Tax Assets Goodwill And Intangible Assets
DeferredTaxAssetsGoodwillAndIntangibleAssets
221000 USD
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2478000 USD
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2007000 USD
CY2021Q4 cdtx Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
595000 USD
CY2020Q4 cdtx Deferred Tax Assets Leasing Arrangements
DeferredTaxAssetsLeasingArrangements
224000 USD
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
4337000 USD
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
795000 USD
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
96948000 USD
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
84815000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96397000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84608000 USD
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
551000 USD
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
207000 USD
CY2021Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
551000 USD
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
207000 USD
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
551000 USD
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
207000 USD
CY2021Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0 USD
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
4400000 USD
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
96400000 USD
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
84600000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
24000000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23300000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
22600000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
19700000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23335000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
22558000 USD
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
16524000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
655000 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
777000 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1074000 USD
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
0 USD
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
4960000 USD
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23990000 USD
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
23335000 USD
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
22558000 USD
CY2021Q4 us-gaap Loss Contingency Pending Claims Number
LossContingencyPendingClaimsNumber
0 claim
CY2021Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P24M
CY2021Q3 cdtx Base Rent Monthly Rate
BaseRentMonthlyRate
103733 USD
CY2021Q3 cdtx Lessee Operating Lease Annual Rate Increase
LesseeOperatingLeaseAnnualRateIncrease
0.03
CY2021 cdtx Number Of Operating Lease Options For Extension
NumberOfOperatingLeaseOptionsForExtension
2 extension
CY2021 cdtx Operating Lease Term Of Extension
OperatingLeaseTermOfExtension
P2Y
CY2021Q4 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.108
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1359000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1400000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2759000 USD
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
289000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2470000 USD
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2287000 USD
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1148000 USD
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1322000 USD
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
2470000 USD
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1000000 USD
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
1200000 USD
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000 USD
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
1000000 USD
CY2021 dei Auditor Firm
AuditorFirmId
42

Files In Submission

Name View Source Status
0001610618-22-000007-index-headers.html Edgar Link pending
0001610618-22-000007-index.html Edgar Link pending
0001610618-22-000007.txt Edgar Link pending
0001610618-22-000007-xbrl.zip Edgar Link pending
cdtx-20211231.htm Edgar Link pending
cdtx-20211231.xsd Edgar Link pending
cdtx-20211231_cal.xml Edgar Link unprocessable
cdtx-20211231_def.xml Edgar Link unprocessable
cdtx-20211231_g1.jpg Edgar Link pending
cdtx-20211231_htm.xml Edgar Link completed
cdtx-20211231_lab.xml Edgar Link unprocessable
cdtx-20211231_pre.xml Edgar Link unprocessable
exhibit10262021-12.htm Edgar Link pending
exhibit1052021-12.htm Edgar Link pending
exhibit2312021-12.htm Edgar Link pending
exhibit3112021-12.htm Edgar Link pending
exhibit3122021-12.htm Edgar Link pending
exhibit3212021-12.htm Edgar Link pending
exhibit3222021-12.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending